GREY:IPHAF - Post by User
Post by
professional11on Jul 03, 2010 11:35pm
620 Views
Post# 17241614
Ulrich, Mitchell
Ulrich, MitchellUlrich left in Feb after the FDA and EMEA applications were filed. His expertise has been (and likely always will be) late stage development (Phase 1-3, NDA) - and he did an outstanding job with Lux. The baton is simply being passed to Mitchell who is a closer (Launch, Market, Sell)
P11
-
President & CEO
— Feb
-
CSO
—
-
President R&D, Executive Board member
BASF Pharma/Knoll
—
-
SVP Global Late Stage Development
HMR/ Aventis
—